Workflow
隐形重仓股
icon
Search documents
震荡市里的暗线机会,顶流基金经理们在打这些“先手牌”
Di Yi Cai Jing· 2025-09-03 12:59
Group 1: Market Overview and Fund Manager Insights - Long-term institutional investors are revealing their holdings as the A-share market experiences fluctuations, with notable adjustments made by prominent fund managers like Zhang Kun and Ge Lan [1][12] - Zhang Kun expresses skepticism about the prevailing pessimistic expectations regarding domestic demand, suggesting that consumer confidence will eventually recover as market conditions improve [12][13] - Ge Lan focuses on the pharmaceutical sector, particularly innovative drugs and medical devices, indicating that these areas will drive growth in the industry [14] Group 2: Fund Holdings and Adjustments - Zhang Kun's management of the E Fund Blue Chip Select has seen a slight reduction in stock positions, with the fund's stock holding ratio decreasing from 94.14% to 92.63%, marking a three-year low [2] - The top ten holdings of the E Fund Blue Chip Select now account for 83.84% of the fund's net value, the highest in the past ten quarters, while the "invisible heavyweights" (ranked 11-20) have significantly decreased in value [2][3] - New additions to the E Fund Blue Chip Select include several technology and consumer stocks, while previous holdings like New秀丽 and 迈瑞医疗 have been removed [3][6] Group 3: Performance of Key Stocks - Among the "invisible heavyweights," 分众传媒 has seen an increase in holdings, while 美团-W has been reduced by 46.43%, dropping to the 12th position [3][4] - Ge Lan's funds have also shown similar trends, with stocks like 爱尔眼科 and 迈瑞医疗 experiencing significant reductions in holdings [7][8] - The performance of key stocks in Ge Lan's portfolio has supported fund value increases, with some stocks like 药明康德 and 华海药业 seeing substantial gains [11] Group 4: Future Outlook and Investment Strategies - Zhang Kun believes that the long-term potential for consumer spending will improve as economic conditions stabilize, emphasizing the importance of consumer income expectations [12][13] - Ge Lan anticipates that the pharmaceutical industry will continue to grow driven by innovation and recovery in consumer demand, with a focus on maintaining a long-term value investment strategy [14]